The company beat analyst estimates on both the top and bottom line and reported a 50 percent year over year growth in clinical testing volume in Q3.
Investigators saw muted negative selection against mutations in genomic data for more than 7,600 tumors, while mining positive selection patterns for cancer driver clues.
The firm is currently marketing its deision support analysis directly to patients and doctors while working on pilot studies with genomics providers to potentially integrate its analysis into their own reports.
A life sciences industrial strategy out this week provided long-term guidance for supporting and enhancing growth in the sector in the UK.
Using blood samples from 200 cancer patients, researchers showed that it is possible to find most early cancer cases with targeted error correction sequencing.
The company said the revenue decline was expected and related to the timing of R&D projects with biopharmaceutical partners.
More than a third of the first 10,000 patients receiving MSK-IMPACT harbored actionable mutations, and 11 percent of the first 5,000 enrolled in a clinical trial.
MultiGen said its test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and NGS methods.
While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said.
Tempus will provide sequencing and analysis for glioblastoma patients in a clinical trial at Duke using engineered poliovirus as a treatment.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.